articleThe LancetJan 24, 2022BRONZE OA

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

JSJeffrey S HeierAMArshad M KhananiCQCarlos Quezada RuizKBKaren BasuPJPhilip J Ferrone

Roche (Ireland) · Vitreous Retina Macula Consultants of New York · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

665
total citations
FWCI
117.71
Percentile
100%
References
26
Citations per year

Authors

316
  • JS
    Jeffrey S HeierCorresponding
  • AM
    Arshad M Khanani
  • CQ
    Carlos Quezada Ruiz
  • KB
    Karen Basu

    Roche (Ireland)

  • PJ
    Philip J Ferrone

    Vitreous Retina Macula Consultants of New York

Topics & keywords

Keywords
  • Macular degeneration
  • Clinical trial
  • Phase (matter)
  • Phases of clinical research
  • Degeneration (medical)
No related works found for this paper.

Funding